The Application of Liquid-Based Cytological Detection for P16, Cytologic Evaluation and High-Risk Human Papillomavirus Testing in Cervical Cancer Screening: A Clinical Evaluation
- PMID: 35924097
- PMCID: PMC9342694
- DOI: 10.2147/IJWH.S365236
The Application of Liquid-Based Cytological Detection for P16, Cytologic Evaluation and High-Risk Human Papillomavirus Testing in Cervical Cancer Screening: A Clinical Evaluation
Abstract
Objective: The aim of this study was to clinically evaluate the application of liquid-based cytology P16, cytologic evaluation, and high-risk human papillomavirus (HR-HPV) testing in cervical cancer screening.
Methods: This study screened 900 women, who attended the outpatient clinic, according to the exclusion criteria of study participants. The study participants' screening results of liquid-based cytology P16, cytologic evaluation, and HR-HPV testing were analyzed. According to the pathological results of the biopsy, the efficacy of different screening strategies for the identification of high-grade lesions was evaluated.
Results: The positive rate of p16 expression increased with the severity of cervical lesions. P16 had the highest sensitivity and negative predictive value in identifying high-grade lesions (98.45% and 99.67%, respectively). Liquid-based Papanicolaou test (LBP), on the other hand, had the lowest sensitivity (85.27%) but the highest specificity (85.88%). HR-HPV's positive predictive value and accuracy rate were the lowest (32.77% and 70.03%, respectively). The difference was statistically significant (P < 0.05). Dual combinations of certain tests were set up for this study; P16+LBP, HPV+LBP, and P16+HPV had sensitivities of 98.45%, 96.90%, and 99.22%, and specificities of 80.29%, 63.42%, and 64.33%, respectively. The P16 screening rates of histological and liquid-based cytology approaches were 75.74%.
Conclusion: Compared with traditional LBP+HPV, the application of a test that solely screen for P16 or the combined screening method that involves the screening of P16 is more effective in identifying high-grade lesions.
Keywords: HR-HPV; biomarkers; liquid-based cytology; p16; screening of high-grade cervical lesions.
© 2022 Zhao et al.
Conflict of interest statement
The authors report no conflicts of intertest in this work.
Similar articles
-
Significance of Triple Detection of p16/ki-67 Dual-Staining, Liquid-Based Cytology and HR HPV Testing in Screening of Cervical Cancer: A Retrospective Study.Front Oncol. 2022 Jun 7;12:915418. doi: 10.3389/fonc.2022.915418. eCollection 2022. Front Oncol. 2022. PMID: 35747800 Free PMC article.
-
Evaluating the Performance of p16INK4a Immunocytochemistry in Cervical Cancer Screening.Cancer Manag Res. 2020 Sep 25;12:9067-9075. doi: 10.2147/CMAR.S273079. eCollection 2020. Cancer Manag Res. 2020. PMID: 33061601 Free PMC article.
-
Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials.Cancer. 2004 Apr 25;102(2):100-8. doi: 10.1002/cncr.20046. Cancer. 2004. PMID: 15098254
-
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Vaccine. 2012. PMID: 23199969 Review.
-
Screening for cervical cancer: new alternatives and research.Salud Publica Mex. 2003;45 Suppl 3:S376-87. doi: 10.1590/s0036-36342003000900012. Salud Publica Mex. 2003. PMID: 14746031 Review.
References
-
- WHO. Comprehensive Cervical Cancer Prevention and Control: A Healthier Future for Girls and Women. Vol. 28. Geneva Switzerland: WHO; 2013:271–272.
-
- Word Health Organization. WHO Guidelines for Screening and Treatment of the Precancerous Lesions for Cervical Cancer Prevention. Geneva: World Health Organization; 2013:60–62. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous